Biogen, Polpharma autoimmune news
Polpharma’s Swiss Pharma International AG subsidiary filed three inter partes review (IPR) petitions with the Patent Trial and Appeal Board (PTAB) of the U.S. Patent and Trademark Office challenging Biogen’s patents covering multiple sclerosis drug Tysabri natalizumab. Swiss Pharma is alleging that claims in Biogen’s U.S. Patents Nos. 8,815,236, 8,900,577 and 8,349,321 are unpatentable on the grounds of obviousness based on prior art. The ‘236 patent relates to a method of use of a stable aqueous formulation of natalizumab with a phosphate buffer, a polysorbate and sodium chloride to treat MS or Crohn’s disease. The ‘577 and ‘321 patents cover immunoglobulin formulations and methods of preparation. The ‘236 and ‘577 patents were issued in 2014, and the ‘321 patent was issued in 2013. ...